2023 Impact Report Patient Reported Outcome (PRO)
This is the largest data report ever released of outcomes following DSR SGB and the combination of DSR and Ketamine, and one of the largest reports on outcomes after Ketamine infusion therapy.
Stella 2023 Impact Report Patient Reported Outcome (PRO)
Treatment Modality Distribution
Single DSR (S-DSR) was the primary intervention delivered for Stella patients treated in 2023 (n=1252). One fifth of the sample received two total DSR treatments, one on the right and one on the left (n=256). Nine percent had a combination of DSR and Ketamine (n=107). Three percent (n=31) had Ketamine infusions only, and one percent had more than 3 DSR procedures (n=14).
Stella 2023 Impact Report Patient Reported Outcome (PRO)
Patient Outcomes Overview
Quality of Life Survey
Long-term quality of life changes
We asked our patients treated between Dec 16' - Aug 22' about the functional changes they've experienced in the months and years after receiving Stella treatment. A total of 227 patients responded to our survey an average of 17 months after completing treatment. Therefore, these data represent relatively long-term post-treatment quality of life changes.
Those who suffer from post-traumatic stress, anxiety and depression deserve the best care that modern neuroscience and psychological expertise can deliver.
Stella's protocols target the biological cause of symptoms instead of just managing them. Following each biological treatment, patients are supported by brief, targeted integration therapy during a window of accelerated healing.